AUS
NZ
UK
CA
USA
IND
Highlights
Molecular Partners AG and Orano Med presented promising preclinical data for their Radio-DARPin Therapeutic candidate, MP0712, at the EANM Congress 2024.
MP0712 demonstrated dose-dependent efficacy, favorable safety profiles, and high specificity for the DLL3 target in biodistribution studies.
Plans are in place to initiate first-in-human studies in 2025, pending regulatory clearance.
Molecular Partners AG (NASDAQ:MOLN) and Orano Med have announced encouraging preclinical data for their Radio-DARPin Therapeutic (RDT) candidate, MP0712, during the EANM Congress 2024. This innovative therapeutic targets delta-like ligand 3 (DLL3), a protein that is overexpressed in a majority of small cell lung cancer tumors and other aggressive neuroendocrine tumors.
The preclinical studies indicated that MP0712 exhibited dose-dependent efficacy along with a favorable safety profile, underscoring its potential as a therapeutic option. Biodistribution studies revealed attractive tumor-to-kidney ratios, which are crucial for minimizing off-target effects and enhancing treatment efficacy. Additionally, MP0712 demonstrated picomolar affinity and high specificity for DLL3, positioning it as a promising candidate for further development in the field of radiopharmaceutical therapy.
In preclinical models that reflect clinically relevant DLL3 expression levels, MP0712 showed strong tumor uptake while maintaining low exposure to the kidneys. This characteristic is particularly important, as it minimizes the risk of toxicity associated with kidney exposure. The treatment was well tolerated at clinically relevant dosages, showcasing strong efficacy when compared to a radiolabeled anti-DLL3 antibody.
Given these positive findings, the companies plan to initiate first-in-human studies in 2025, contingent upon receiving the necessary regulatory approvals. The potential of MP0712 as a targeted radiopharmaceutical therapy offers hope for improving outcomes in patients with small cell lung cancer and other neuroendocrine tumors. The ongoing collaboration between Molecular Partners AG and Orano Med aims to advance this promising candidate toward clinical application, contributing to the evolving landscape of cancer therapeutics.
